Chemoprevention of lung cancer: Current status and future prospects

Lung Cancer

Volumn 42, Issue 2 SUPPL., 2003, Pages 71-79

  Van Zandwijk, Nico ^a   Hirsch, Fred R ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Chemoprevention; Current status; Lung cancer

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CELL RECEPTOR; CHALCONE; ETRETINATE; FENRETINIDE; FLAVANOID; ISOTRETINOIN; RETINAL; RETINOIC ACID; RETINOID; RETINOL; RETINOL PALMITATE; SELENIUM;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC TEST; DIET; DIETARY INTAKE; GENE MUTATION; HUMAN; LUNG CARCINOMA; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0242468796     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00307-6     Document Type: Conference Paper

References (82)

1. Peto R., Darby S., Deo H., Silcocks P., Whitley E., Doll R. Smoking, smoking cessation and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br. Med. J. 321:2000;323-329.
2. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91:1999;1194-1210.
3. Spivack S.D., Fasco M.J., Walker V.E., Kaminsky L.S. The molecular epidemiology of lung cancer. Crit. Rev. Toxicol. 27:1997;319-365.
4. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung, Cancer 1993;72:432-438.
5. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo(a) pyrene adducts in n lung cancer hotspots in p53. Science. 274:1996;430-432.
6. Wei Q., Cheng L., Amos C.I., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. J. Natl. Cancer Inst. 92:2000;1764-1772.
7. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61:2001;1354-1357.
8. Ooi W.L., Elston R.C., Chen V.W., Bailey-Wilson J.E., Rothschild H. Increased familial risk for lung cancer. J. Natl. Cancer Inst. 76:1986;217-222.
9. Osann K.E. Lung cancer in women: the importance of smoking, family history of cancer and medical history of respiratory disease. Cancer Res. 51:1991;4893-4897.
10. Wistuba I.I., Lam S., Behrens C., et al. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1997;1366-1373.
11. Strauss G., DeCamp M., Dibiccaro E., et al. Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers! Proc. Am. Soc. Clin. Oncol. 14:1995;362.
12. Slaughter D.P., Southwick H.W., Smejkal W. 'Field cancerization' in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer. 6:1953;963-968.
13. Auerbach O., Gere J.B., Foreman J.B., et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N. Engl. J. Med. 256:1957;98-104.
14. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Clinical perspectives of recent advances in molecular biology and radiology for early detection of lung cancer. Clin. Cancer Res. 7:2001;5-22.
15. Hung J., Kishimoto Y., Sugio K., et al. Allele-specific loss in chromosome 3p deletions occur at an early stage in the pathogenesis of lung cancer. J. Am. Med. Assoc. 273:1995;558-563.
16. Kishimoto Y., Sugio K., Hung J.Y., et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small cell lung cancer. J. Natl. Cancer Inst. 87:1995;1224-1229.
17. Sozzi G., Sard L., de Gregorio L., et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:1997;5207-5212.
18. Wu X., Zhao H., Amos C.I., et al. p 53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 94:2002;681-690.
19. Virmani A.K., Rathi A., Zochbauer-Muller S., et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92:2001;1303-1307.
20. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancer. Cancer Res. 61:2001;249-255.
21. Soria J.C., Rodrigues M., Liu D.D., Lee J.J., Hong W.K., Mao L. Aberrant promotor of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 62:2002;351-355.
22. Belinsky S., Palmisano W.A., Gilliland F.D., et al. Aberrant promotor methylation in bronchial epithelium from current and former smokers. Cancer Res. 62:2002;2370-2377.
23. Block G., Patterson B., Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer. 18:1992;1-41.
24. Cancer chemopreventive agents. In: Kelloff GJ, Boone CW editors. Drug development status and future prospects. J. Cell. Biochem. suppl 1995; 22: 262.
25. Spitz M.R., Duphorne C.M., Detry M.A., et al. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione transferase polymorphisms in lung cancer risk in current smokers. Cancer Epidemiol. Biomarkers Prevent. 9:2000;1017-1020.
26. Hong YS, Ham YA, Choi JH, Kim J. Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non small cell lung cancer cell lines, Exp. Mol. Med. 2000;32:127-134.
27. Fujiki H., Suganuma M., Okabe S., et al. Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. Mutat. Res. 480-481:2001;299-304.
28. Sinha R, Kulldorff M, Swanson CA, Curtin J, Brownson RC, Alavan MC. Dietary heterocyclic amines and the risk of lung cancer among Missouri women, Cancer Res. 2000;60:3753-3756.
29. Feskanich D., Ziegler R.G., Michaud D.S., et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J. Natl. Cancer Inst. 92:2000;1812-1823.
30. Sporn M.B., Dunlop N.M., Newton D.L., Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35:1976;1332-1338.
31. Gudas L.J. Retinoids and vertebrate development. J. Biol. Chem. 269:1994;15 399-15 402.
32. Xu X.C., Sozzi G., Lee J.S., et al. Suppression of retinoic acid receptor beta in non-small cell lung cancer in vivo: implications for lung cancer development. J. Natl. Cancer Inst. 89:1997;624-629.
33. Xu X.C., Lee J.S., Lee J.J., et al. Nuclear retinoid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J. Natl. Cancer Inst. 91:1999;1317-1321.
34. Khuri F.R., Lee J.S., Lippman S.M., et al. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol. Biomarkers Prevent. 10:2001;311-318.
35. Hong W.K., Lippman J.M., Itri L., et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 323:1990;795-801.
36. Pastorino U., Infante I., Maioli M., et al. Adjuvant treatment of stage I lung cancer with high dose vitamin A. J. Clin. Oncol. 11:1993;1216-1222.
37. Heimburger D.C., Alexander C.B., Birch R., et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. J. Am. Med. Assoc. 259:1988;1525-1530.
38. Arnold A.M., Browman G.P., Levine M.N., et al. The effect of the synthetic retinoid etrenitate on sputum cytology: results from a randomized trial. Br. J. Cancer. 65:1992;737-743.
39. Lee J.S., Lippman S.M., Benner S.E., et al. Randomized placebo controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J. Clin. Oncol. 12:1994;937-945.
40. Mc Larthy J.W., Holiday D.B., Girard W.M., Yanagihara R.H., Kummet T.D., Greenberg S.D. Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am. J. Clin. Nutr. 62:(6 suppl):1995;1431S-1438S.
41. Kurie J.M., Lee Js., Khuri F.R., et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin. Cancer Res. 6:2000;2973-2979.
42. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:1994;1029-1035.
43. Omenn G.S., Goodman G.E., Thornquist M., et al. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334:1996;1150-1155.
44. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
45. Pastorino U. Beta-carotene and the risk of lung cancer. J. Natl. Cancer Inst. 89:1997;456-457.
46. Wang X.D., Liu C., Bronson R.T., Smith D.E., Krinsky N.I., Russell R.M. Retinoid signalling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J. Natl. Cancer Inst. 91:1999;60-66.
47. Van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Natl. Cancer Inst. 92:2000;977-986.
48. Lippman S.M., Lee J.J., Karp D.D., et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 93:2001;605-618.
49. Van Zandwijk N, Pastorino U, De Vries N, Van Tinteren H. Smoking analysis of EUROSCAN, the chemoprevention study of the EORTC Head & Neck and Lung Cancer Cooperative groups in patients with cancer of the upper and lower airways. Abstracts 9th World Conference on Lung Cancer, Tokyo, Japan Lung Cancer 2000;29(suppl):219 # 749.
50. IARC Working Group on the Evaluation of Cancer Preventive Agents. IARC handbooks of cancer prevention, In: Retinoids 1999;4:IARC, Lyon, France, p. 331.
51. Soria J.C., Moon C., Wang L., et al. Effects of N-(4-hydroxyphenyl) retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J. Natl. Cancer Inst. 93:2001;1257-1263.
52. Tuma R.S. Retinoids and lung cancer: targeting the right population. J. Natl. Cancer Inst. 94:2002;969-970.
53. Kurie JM, Lotan R, Lee JJ, et al. Randomized, placebo-controlled trial of 9-cis retinoic acid (9cRA) versus 13-cis retinoic (13 cis RA) plus alpha tocopherol (AT) in the reversal of biomarkers of bronchial preneoplasia in former smokers. Proc. Am. Soc. Clin. Oncol. USA: Orlando, Fl, 2002;21:295a #1177.
54. Degos L., Wang Z.Y. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 20:2001;7140-7145.
55. Khuri F.R., Rigas J.R., Figlin R.A., et al. Multi-institutional phase I/II Trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 19:2001;2626-2637.
56. Lippman S.M., Heyman R.A., Kurie J.M. Retinoids and chemoprevention: clinical and basic studies. J. Cell. Biochem. 22:1995;1-10.
57. Dahl A.R., Grossi I.M., Houchens D.P., et al. Inhaled istretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin. Cancer Res. 6:2000;3015-3024.
58. Wang DL, Marko M, Dahl AR, et al. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors, Clin. Cancer Res. 2000;6:3636-3645.
59. Brooks Ad., Tong W., Benedetti F., Kaneda Y., Miller V., Warrell R.P. Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother. Pharmacol. 46:2000;313-318.
60. Dimery I.W., Hong W.K., Lee J.J., et al. Phase I trial of alpha-tocopherol effects on 13-cis retinoic acid toxicity. Ann. Oncol. 8:1997;85-89.
61. Shin D.M., Khuri F.R., Murphy B., et al. Combined interferon-alpha, 13-cis retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J. Clin. Oncol. 19:2001;3010-3017.
62. Shamberger R.J., Frost D.V. Possible protective effect of selenium against human cancer. Can. Med. Assoc. J. 100:1969;682.
63. van den Brandt P.A., Goldbohm R.A., van 't Veer P., et al. Prospective cohort study on selenium status and the risk of lung cancer. Cancer Res. 53:1993;4860-4865.
64. Clark L.C., Combs G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J. Am. Med. Assoc. 276:1996;1957-1963.
65. Hoque A., Albanes D., Lippman S.M., et al. Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT). Cancer Causes Control. 12:2001;627-633.
66. De Flora S., Izotti A., D'Agostini F., Balansky R.M. Mechanism of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis. 22:2001;999-1013.
67. Van Schooten FJ, Nia AB, De Flora S, et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers, Cancer Epidemiol. Biomarkers Prevent. 2002;11:167-175.
68. Kennsler T.W., Groopman J.D., Roebuck B.D. Chemoprotection by oltipraz and other dithioleethiones. Wattenberg L., Lipkin M., Boone C., Kelloff G. Cancer chemoprevention. 1992;205-225 CRC Press, Boca Raton (FL).
69. Pepin P., Bouchard L., Nicole P., Castonguay A. Effects of sulindac and oltipraz on the tumorigenicity of 4-(metylnitrosamino)1-(3 pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis. 13:1992;341-348.
70. Lam S., MacAulay C., le Riche J.C., et al. A randomized phase IIb trial of anethole dithioleethione in smokers with bronchial dysplasia. J. Natl. Cancer Inst. 94:2002;1001-1009.
71. Epstein J.B., Decoteau W.E., Wilkinson A. Effect of sialor in treatment of xerostomia in Sjögren's syndrome. Oral Surg. Oral Med. Oral Pathol. 56:1983;495-499.
72. Hecht S.S., Upadhyaya P., Wang M., et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 23:2002;1455-1461.
73. Hirsch F.R., Prindiville S., Miller Y.E., et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J. Natl. Cancer Inst. 93:(18):2001;1385-1391.
74. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., Bunn P.A. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 29:(suppl 4):2002;3-14.
75. Baselga J., Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr. Oncol. Rep. 4:2002;317-324.
76. Dannenberg AJ, Alturki NK, Subbaramaiah K. Selective inhibitors of COX-2: New applications in oncology. In: Educational Book Am. Soc. Clin. Oncol. 2001;21-27.
77. Hida T., Yatabe Y., Achiwa H., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
78. Hasturk S., Kemp B., Kalapurakal S., Kurie J.M., Hong W.K., Lee J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non small cell lung carcinoma. Cancer. 94:2002;1023-1031.
79. Schuller H.M., Tithof P.K., William M., et al. The tobacco specific carcinogen 4-(methulnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 59:1999;4510-4515.
80. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Koenig K.L., Shore R.E. Aspirin and lung cancer in women. Br. J. Cancer. 87:2002;49-53.
81. Harris R.E., Beebe-Donk J., Schuller H.M. Chemoprevention by non-steroidal ant-inflammatory drugs in cigarette smokers. Oncol. Rep. 9:2002;693-695.
82. Hirsch FR, Prindiville SA, Byers T, et al. Sputum cytology as a marker of risk for lung cancer: preliminary results from the University of Colorado high risk cohort study. Proceedings Am Soc Clin Oncol, USA: Orlando, Fl, 2002;21:301a # 1201.